# Andrew Hack > Andrew Hack is a Series C investor at Bain Capital Life Sciences backing Biotechnology. See 9 investments, check sizes, portfolio and contact details… - Type: Angel Investor - Fund: [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) - Location: Boston, United States - Total investments: 9 - Last investment: Apr 2025 - Lead investor: 67% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/andrew-hack-md-phd-079226a - Website: https://www.baincapital.com/people/andrew-hack-md-phd Andrew Hack is a Series C investor at Bain Capital Life Sciences in Boston focused on Biotechnology and Health Care. Andrew Hack joined Bain Capital in 2019 as Managing Director of Bain Capital Life Sciences. From 2015 to 2019, he was Chief Financial Officer of Editas Medicine (Nasdaq: EDIT). ## Contacts 5 contacts available for Andrew Hack: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/andrew-hack?utm_source=investor_profile ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 5 | 56% | | Health Care | 4 | 44% | | Therapeutics | 3 | 33% | | Life Science | 2 | 22% | | Pharmaceutical | 2 | 22% | 10 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series C | 3 | 33% | | Series B | 2 | 22% | | Series D | 2 | 22% | | Series A | 1 | 11% | | Venture - Series Unknown | 1 | 11% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 5 | 56% | | Germany | 1 | 11% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Merida Biosciences | Merida Biosciences is a new biotech company focused on developing precision treatments, particularly for autoimmune diseases. The company utilize a protein engineering platform to create unique Fc therapeutics, aiming to selectively bind to specific antibodies. | $121M | Series A | Apr 08, 2025 | | | JenaValve Technology | JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $100M | Series C | Aug 31, 2022 | | | Nuvalent | Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing arobust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. | $135M | Series B | May 11, 2021 | | | Xilio Therapeutics | Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of provenimmuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatmentXilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States. | $95M | Series C | Feb 24, 2021 | | | Affinivax | Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases.This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existingvaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today.The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform. | $226M | Series C | Jan 08, 2021 | | | Atea Pharmaceuticals | Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNAviruses.Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts. | $215M | Series D | May 20, 2020 | | | Affinivax | Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases.This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existingvaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today.The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform. | $120M | Series B | Apr 23, 2020 | | | JenaValve Technology | JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $50M | Series D | Feb 05, 2020 | | | JenaValve Technology | JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $50M | Venture - Series Unknown | Feb 05, 2020 | | 9 of 9 investments shown. ## Co-investors - [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 3 deals together - [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 3 deals together - [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 3 deals together - [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 3 deals together - [Viking Global Investors](https://shizune.co/investors/profile/viking-global-investors) — VC Fund, 3 deals together - [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 2 deals together ## About Bain Capital Life Sciences VC Fund · Boston, United States Bain Capital Life Sciences specializes in buyouts, inflexion capital, growth capital, turnaround investments, and private equity. It invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enablethat innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of the Bain Capital Life Sciences team enables it to deliver targeted capital and value-added strategic support to companies around critical phases of growth and inflexions in value. 5 contacts available at Bain Capital Life Sciences. | Name | Title | Profile | | --- | --- | --- | | Adam Koppel | Managing Director | https://shizune.co/investors/profile/adam-koppel | | Andrew Hack | Managing Director | — | | Benjamin Lund | Partner | — | | Coleman Mark | Founder | — | | Eric Kriss | Founder | — | ## Similar investors ### Similar stage - [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund - [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund - [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund ## FAQ ### What does Andrew Hack invest in? Andrew Hack invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### How do I contact Andrew Hack? Public channels for Andrew Hack include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox. ### When did Andrew Hack last invest? The most recent investment recorded for Andrew Hack closed in Apr 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co